Meda Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Meda Pharmaceuticals's estimated annual revenue is currently $59.3M per year.
- Meda Pharmaceuticals's estimated revenue per employee is $201,000
Employee Data
- Meda Pharmaceuticals has 295 Employees.
- Meda Pharmaceuticals grew their employee count by 0% last year.
Meda Pharmaceuticals's People
Name | Title | Email/Phone |
---|
Meda Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5M | 25 | -11% | N/A | N/A |
#2 | $35.8M | 178 | 8% | N/A | N/A |
#3 | $5.4M | 27 | -25% | N/A | N/A |
#4 | $4180M | 14516 | 1% | $550M | N/A |
#5 | $12.5M | 62 | 15% | N/A | N/A |
#6 | $6.7M | 119 | -37% | $199.6M | N/A |
#7 | $9.4M | 47 | 7% | N/A | N/A |
#8 | $10.3M | 51 | 6% | N/A | N/A |
#9 | $106.3M | 529 | 16% | N/A | N/A |
#10 | $15.5M | 77 | 20% | N/A | N/A |
What Is Meda Pharmaceuticals?
MedPointe is a specialty pharmaceutical company that develops, markets and sells branded prescription therapeutics. Although the company was founded in 2001, it draws upon a long history. It entered the market with the acquisition of Carter-Wallace, Inc., a long-established enterprise. MedPointe is headquartered in Somerset, New Jersey, in the heart of the nation's pharmaceutical corridor.
keywords:N/AN/A
Total Funding
295
Number of Employees
$59.3M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Meda Pharmaceuticals News
Sun Pharmaceutical Industries; Meda Pharmaceuticals; Dr. Reddyâs Laboratories; Allergan; Taiwan Liposome Company; Teva Pharmaceutical; Celgene...
Meda Pharmaceuticals Inc; Bausch & Lomb Inc; Cigna; Similasan Corporation; Visine; Alcon; Viva Opti-Free; Bausch & Lomb; Systane; Rite Aid...
Glaxosmithkline; Sanofi; Alk-abell; Meda Pharmaceuticals; Adamis Pharmaceuticals; Allergy Therapeutics; Almirall; Ampio; Astrazeneca; Amneal...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $97.9M | 312 | 23% | N/A |
#2 | $59.3M | 327 | 2% | N/A |
#3 | $60.2M | 332 | 18% | N/A |
#4 | $146.9M | 356 | 26% | N/A |
#5 | $155M | 378 | 3% | N/A |